Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Bagsværd, Denmark (ots/PRNewswire) -

- Results published in Diabetes, Obesity and Metabolism

Newly published data from real-world European clinical practice
has shown that Xultophy® (insulin degludec/liraglutide) significantly
reduced blood sugar levels in people with type 2 diabetes after six
months.[1] The study looked at people with type 2 diabetes who were
treatment-naïve or who had been switched to treatment with Xultophy®
from any combination of oral antidiabetic drugs, glucagon-like
peptide-1 (GLP-1) analogues, and/or insulin regimens in real-world
clinical practice.[1]

In the study population, Xultophy® delivered a significant overall
decrease in mean blood sugar (HbA1c) of 0.9% to 7.5% at six months.
Regardless of which treatment the study participants were switched
from, the average decrease in blood sugar was significant.[1] The
average dose of Xultophy® was 30 dose steps (representing 30 units of
insulin) at six months, significantly lower than 50 dose steps which
is the maximum approved dose of Xultophy®.[1]

"It's exciting to see that Xultophy® delivers significant benefits
to people with type 2 diabetes in such a short period of time and in
a real-world setting, providing better blood sugar control with just
one injection per day regardless of previous treatment," said Mads
Krogsgaard Thomsen, executive vice president and chief science
officer at Novo Nordisk.

Hypoglycaemia (low blood sugar) rates were reduced by 82% in the
six month period after initiating Xultophy®, compared to the six
month period before. Furthermore, average body weight was
significantly reduced by 0.7 kg after six months of treatment vs
baseline.[1]

About the EXTRA study

The European Xultophy® Treatment Retrospective Audit (EXTRA) study
was a European, multicentre, retrospective chart review which
included 611 people with type 2 diabetes >= 18 years of age, who
started on Xultophy® at least six months prior to the start of the
study. Blood sugar levels, body weight and rate of hypoglycaemic
events were measured at baseline (up to six months before starting on
Xultophy®) and at 3, 6, 9 and 12 months after initiating Xultophy®.
Data was collected from clinics in Germany (n=450), Switzerland
(n=84), the UK (n=44), Austria (n=19) and Sweden (n=14).[1]

The study was published in the peer-reviewed journal Diabetes,
Obesity and Metabolism.[1]

About Xultophy®

Xultophy® is a once-daily single injection fixed-ratio combination
of long-acting insulin degludec and the glucagon-like
peptide-1(GLP-1) receptor agonist liraglutide in one pen. It is
indicated for the treatment of adults with type 2 diabetes mellitus
to improve glycaemic control in combination with oral
glucose-lowering medicinal products when these alone or combined with
a GLP-1 receptor agonist or basal insulin do not provide adequate
glycaemic control. Xultophy® can be administered at any time of the
day with or without meals, preferably at the same time of the day.[2]

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat other serious chronic conditions: haemophilia, growth
disorders and obesity. Headquartered in Denmark, Novo Nordisk employs
approximately 41,400 people in 77 countries and markets its products
in more than 165 countries. For more information, visit
novonordisk.com
(https://www.novonordisk.com/patients/diabetes-care/type-2.html),
Facebook (http://www.facebook.com/novonordisk), Twitter
(http://www.twitter.com/novonordisk), LinkedIn
(http://www.linkedin.com/company/novo-nordisk), YouTube
(http://www.youtube.com/novonordisk)

References

1. Price H, Bluher M, Prager R, et al. Use and effectiveness of
a fixed-ratio combination of insulin degludec/liraglutide (IDegLira)
in a real-world population with type 2 diabetes: Results from a
European, multicentre, retrospective chart review study. Diabetes
Obes Metab. 2017. http://dx.doi.org/10.1111/dom.13182.

2. EMA. Xultophy® Summary of Product Characteristics. Available
at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Produ
ct_Information/human/002647/WC500177657.pdf. Last accessed: December
2017.

Further information

Media:

Katrine Sperling

+45-4442-6718

krsp@novonordisk.com

Åsa Josefsson

+45-3079-7708

aajf@novonordisk.com

Investors:

Peter Hugreffe Ankersen

+45-3075-9085

phak@novonordisk.com

Hanna Ögren

+45-3079-8519

haoe@novonordisk.com

Anders Mikkelsen

+45-3079-4461

armk@novonordisk.com

Christina Kjær

+45-3079-3009

cnje@novonordisk.com

Kasper Veje (US)

+1-609-235-8567

kpvj@novonordisk.com

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Novo Nordisk A/S, übermittelt durch news aktuell